Mangalam Drugs Q1 Results FY27: Revenue Rs 57 crore, Net Loss Rs 7 Crore on Consolidated Basis
- August 14, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Mangalam Drugs Q1 results: Revenue Rs 57 crore (-0.40% YoY). PAT Rs 7 Cr (+44.64% YoY). GP Rs -3 crore. CMP Rs 27.16 (-0.40%).
Quick Answer
Mangalam Drugs Q1 results for FY27, declared August 12, 2026, show revenue of Rs 57 crore, down 0.4% year on year from Rs 57 crore a year ago. Net loss was net loss of Rs 7 crore, up 44.64% year on year on a consolidated basis. Gross profit stood at Rs -3 crore for the April to June 2026 quarter. The stock closed at Rs 27.16, down 0.4% on results day.
Mangalam Drugs Q1 results for FY27 were declared on August 12, 2026, covering the April to June 2026 quarter. Revenue came in at Rs 57 crore, down 0.4% year on year from Rs 57 crore a year ago. A net loss of net loss of Rs 7 crore was posted on a consolidated basis. Gross profit was Rs -3 crore for the quarter.
The Mangalam Drugs Q1 results analysis below covers financial highlights, key business drivers, FY27 outlook, and investor risks. The Nifty Pharma index reflects the broader Pharmaceuticals sector backdrop against which these results should be read.
Click Here – Get Free Investment Predictions
Mangalam Drugs Q1 Results: Financial Highlights
| Metric | Q1 FY27 (Jun 26) | Q1 FY26 (Jun 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 57 Cr | Rs 57 Cr | -0.40% YoY |
| Gross Profit | Rs -3 Cr | Rs -8 Cr | +64.46% YoY |
| Net Profit (PAT) | Rs -7 Cr | Rs -13 Cr | +44.64% YoY |
Source: Company filing, August 12, 2026. Figures in Rs Crore. Consolidated basis.
Mangalam Drugs Q1 Results: Performance Analysis
Mangalam Drugs Q1 results show revenue that remained broadly flat during the April to June 2026 period. Gross profit improved, pointing to improved cost management during the quarter. A net loss of Rs 7 crore was posted, reflecting near-term profitability pressure.
A detailed look at Mangalam Drugs Q1 results reveals that revenue was under pressure from demand or pricing challenges. The consolidated numbers provide a group-level view of the company’s financial position.
Investors analysing these quarterly results for FY27 signals should focus on the gross margin trajectory and what it implies for earnings over the next two to three quarters. These numbers serve as the baseline for full-year FY27 projections and comparison with sector peers.
Check Live Financials on the Univest Screener
Key Business Factors This Quarter
API and Formulation Volume — This was a key driver this quarter. Weakness here weighed on revenue performance. Investors should track changes to this metric in subsequent quarterly disclosures.
Domestic and Export Mix — This had a direct bearing on gross margins. Improvement here helped contain costs and supported the quarterly gross profit level. Management’s approach to this factor will shape margin outcomes in the quarters ahead.
Cost Rationalisation — This factor shaped the overall operating environment this quarter. Any significant change here will likely reflect in the next set of quarterly numbers.
Dividend Details
The quarterly results declared on August 12, 2026 did not include an interim dividend announcement from Mangalam Drugs. Companies in the Pharmaceuticals sector typically announce dividends alongside Q4 or full-year results. Investors should monitor official BSE or NSE filings for future dividend updates from this company.
FY27 Outlook for Mangalam Drugs
Mangalam Drugs Q1 results for FY27 provide ongoing profitability pressure for the full fiscal year. The Pharmaceuticals sector broadly faces steady demand conditions heading into H2 FY27, which provides useful context for interpreting the April to June quarter print.
Investors using these Q1 results as a base for FY27 projections for Mangalam Drugs should note that if return to profitability will require both revenue recovery and sharper cost discipline beyond what the current Q1 results reflect. Management commentary on capacity, order book, and pricing guidance — when available — will help refine full-year estimates.
Mangalam Drugs Stock Performance After Q1 Results
Mangalam Drugs’s share price closed down at Rs 27.16, down 0.4% on August 12, 2026, the day the Q1 results were announced. The market adopted a cautious stance. Such movements on results day reflect immediate sentiment and may not represent the long-term investment picture.
Investors can track the live share price and full financial data on the NSE and BSE portals. Always verify current prices and exchange filings before any investment decision.
Download the Univest iOS App or Univest Android App to track Mangalam Drugs’s live share price.
Key Risks to Watch After the Q1 Results
API Pricing Pressure
This risk could weigh on revenue or margins if it intensifies. Investors should track how the company addresses this in upcoming quarterly disclosures.
Regulatory Compliance Risk
This represents a potential headwind for the business in the quarters ahead. If it materialises, it could alter the earnings trajectory visible in the recent numbers.
Loss Reduction Pace
This structural risk is shared with peers in the Pharmaceuticals sector. It warrants monitoring as it can influence fair value and longer-term earnings potential.
Conclusion
Mangalam Drugs Q1 results for FY27 reflect the challenges the company currently faces. A net loss of Rs 7 crore underscores the near-term profitability pressure. A sustained recovery will depend on Pharmaceuticals sector conditions and company-specific execution. Investors reviewing these Mangalam Drugs Q1 results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Mangalam Drugs Q1 Results
What were Mangalam Drugs Q1 results for FY27?
Ans. Mangalam Drugs Q1 results for FY27 show revenue of Rs 57 crore, down 0.4% year on year and a net loss of Rs 7 crore on a consolidated basis. Declared August 12, 2026.
When were the Q1 FY27 results declared for Mangalam Drugs?
Ans. The Q1 FY27 results for Mangalam Drugs were declared on August 12, 2026, covering the April to June 2026 quarter on a consolidated basis.
What was the revenue in the Q1 FY27 quarter?
Ans. Revenue for the April to June 2026 quarter was Rs 57 crore, down 0.4% year on year from Rs 57 crore a year ago. Refer to official BSE or NSE filings for complete financial data.
What was the net profit in Q1 FY27?
Ans. Net profit was a loss of Rs 7 crore on a consolidated basis, up 44.64% year on year year on year. Refer to official exchange filings for full details.
Did Mangalam Drugs Q1 results include a dividend announcement?
Ans. No interim dividend was declared as part of these quarterly results for Mangalam Drugs. Dividends are typically announced with annual results. Check BSE or NSE filings for updates.
How did the stock react to Q1 FY27 results?
Ans. The stock closed down at Rs 27.16, down 0.4% on August 12, 2026. Stock movements on results day reflect immediate sentiment and may not indicate long-term direction.
What are the key risks highlighted after Q1 FY27?
Ans. Key risks after Q1 FY27 include api pricing pressure, regulatory compliance risk, and loss reduction pace. Track quarterly disclosures and management commentary for how these risks evolve.
Where can I find the complete Q1 FY27 financial data for Mangalam Drugs?
Ans. Mangalam Drugs Q1 results data is available on BSE (bseindia.com) and NSE (nseindia.com) filing portals. The Univest screener also provides a curated financial data snapshot.
